Tumor histology in lymph vessels and lymph nodes for the accurate prediction of outcome among breast cancer patients treated with neoadjuvant chemotherapy

Cancer Science

Volumn 100, Issue 10, 2009, Pages 1823-1833

  Tamura, Nobuko ^a,b   Hasebe, Takahiro ^b   Okada, Nao ^a   Houjoh, Takashi ^a   Akashi Tanaka, Sadako ^a   Shimizu, Chikako ^a   Shibata, Tatsuhiro ^c   Sasajima, Yuko ^a   Iwasaki, Motoki ^b   Kinoshita, Takayuki ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER   (Japan)

^c NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE;

ACCURACY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST BIOPSY; BREAST CANCER; CANCER GRADING; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEMALE; FIBROSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPH VESSEL; MAJOR CLINICAL STUDY; MASTECTOMY; MITOSIS; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PREDICTION; PRIORITY JOURNAL; RECURRENCE RISK; RISK ASSESSMENT; TREATMENT OUTCOME; TUMOR CELL; TUMOR EMBOLISM; TUMOR GROWTH; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; LYMPHATIC METASTASIS; LYMPHATIC VESSELS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL;

EID: 70349587207     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01264.x     Document Type: Article

References (40)

1. Ragaz J, Baird R, Rebbeck P, Goldie A, Coldman A, Spinelli J. Preoperative adjuvant chemotherapy (neoadjuvant) for carcinoma of the breast: rationale and safety report. Recent Results Cancer Res 1985, 98:99-105.
2. Ragaz J. Preoperative (neoadjuvant) chemotherapy for breast cancer: outline of the British Columbia Trial. Recent Results Cancer Res 1986, 103:85-94.
3. Ferriere JP, Assier I, Cure H. Primary chemotherapy in breast cancer: correlation between tumor response and patient outcome. Am J Clin Oncol 1998, 21:117-20.
4. Daidone MG, Silvestrini R, Luisi A. Changes in biological markers after primary chemotherapy for breast cancers. Int J Cancer 1995, 61:301-5.
5. Cavailles V, Gompel A, Portois MC. Comparative activity of pulsed or continuous estradiol exposure on gene expression and proliferation of normal and tumoral human breast cells. J Mol Endocrinol 2002, 28:165-75.
6. Koukourakis MI, Simopoulos C, Polychronidis A. The effect of trastuzumab/docatexel combination on breast cancer angiogenesis: dichotomus effect predictable by the HIFI alpha/VEGF pre-treatment status?. Anticancer Res 2003, 23:1673-80.
7. Petit T, Borel C, Ghnassia JP. Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting. Clin Cancer Res 2001, 7:1577-81.
8. Chollet P, Amat S, Cure H. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer 2002, 86:1041-6.
9. Penault-Llorca F, Vincent-Salomon A. Roles of the pathologist in neoadjuvant chemotherapy: evaluation of response, prognostic and predictive factors. Ann Pathol 2003, 23:555-63.
10. Bollet MA, Sigal-Zafrani B, Gambotti L. Pathological response to preoperative concurrent chemo-radiotherapy for breast cancer: results of a phase II study. Eur J Cancer 2006, 42:2286-95.
11. Hasebe T, Yamauchi C, Iwasaki M. Grading system for lymph vessel tumor emboli for prediction of the outcome of invasive ductal carcinoma of the breast. Hum Pathol 2008, 39:427-36.
12. Hasebe T, Sasaki S, Imoto S. Histological characteristics of tumor in vessels and lymph nodes are significant predictors of progression of invasive ductal carcinoma of the breast: a prospective study. Hum Pathol 2004, 35:298-308.
13. Sobin LH, Wittekind CH. TNM Classification of Malignant Tumors 2002, 131-141. eds, Geneva, Wiley-Liss
14. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer. Br J Cancer 1957, 11:359-77.
15. Gilchrist KW, Gray R, Fowble B. Tumor necrosis is a prognostic predictor for early recurrence and death in lymph node-positive breast cancer: a 10-year follow-up study of 728 eastern cooperative oncology group patients. J Clin Oncol 1993, 11:1929-35.
16. Hasebe T, Tsuda H, Hirohashi S. Fibrotic focus in infiltrating ductal carcinoma of the breast: a significant histopathological prognostic parameter for predicting the long-term survival of the patients. Breast Cancer Res Treat 1998, 49:195-208.
17. Hasebe T, Sasaki S, Imoto S. Prognostic significance of fibrotic focus in invasive ductal carcinoma of the breast: a prospective observational study. Mod Pathol 2002, 15:502-16.
18. Yamauchi C, Hasebe T, Iwasaki M. Accurate assessment of lymph vessel tumor emboli in invasive ductal carcinoma of the breast according to tumor areas, and their prognostic significance. Hum Pathol 2007, 38:247-59.
19. Fisher B. Biological and clinical considerations regarding the use of surgery and chemotherapy in the treatment of primary breast cancer. Cancer 1977, 40:574-87.
20. Fisher B. Adjuvant chemotherapy in the primary management of breast cancer. Med Clin North Am 1977, 61:953-65.
21. Kurosumi M. Significance of histopathological evaluation in primary therapy for breast cancer - recent trends in primary modality with pathological complete response (pCR) as endpoint. Breast Cancer 2004, 11:139-47.
22. Wolff AC, Hammond ME, Schwartz JN. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007, 131:18-43.
23. Cox DR. Regression models and life-tables. J R Stat Soc 1972, 34:187-220.
24. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-81.
25. Lee AHS, Pinder SE, Macmillan RD. Prognostic value of lymphovascular invasion in women with lymph node negative invasive breast carcinoma. Eur J Cancer 2006, 42:357-62.
26. EI-Gohary YM, Metwally G, Saad RS. Prognostic significance of intratumoral and peritumoral lymphatic density and blood vessel density in invasive breast carcinomas. Am J Clin Pathol 2008, 129:578-86.
27. Amaout-Alkarain A, Kahn HJ, Narod SA. Significance of lymph vessel invasion identified by the endothelial lymphatic marker D2-40 in node negative breast cancer. Mod Pathol 2007, 20:183-91.
28. Hasebe T, Sasaki S, Imoto S. Characteristics of tumors in lymph vessels play an important role in the tumor progression of invasive ductal carcinoma of the breast: a prospective study. Mod Pathol 2002, 15:904-13.
29. Hasebe T, Sasaki S, Imoto S. Significance of nodal metastatic tumor characteristics in nodal metastasis and prognosis of patients with invasive ductal carcinoma of the breast. Cancer Sci 2003, 94:181-7.
30. Hasebe T, Sasaki S, Imoto S. Proliferative activity of intratumoral fibroblasts is closely correlated with lymph node and distant organ metastases of invasive ductal carcinoma of the breast. Am J Pathol 2000, 156:1701-10.
31. Hasebe T, Sasaki S, Imoto S. Highly proliferative fibroblasts forming fibrotic focus govern metastasis of invasive ductal carcinoma of the breast. Mod Pathol 2001, 14:325-37.
32. Hasebe T, Imoto S, Ogura T. Significance of basic fibroblast growth factor and fibroblast growth factor receptor protein expression in the formation of fibrotic focus in invasive ductal carcinoma of the breast. Jpn J Cancer Res 1997, 88:877-85.
33. Finak G, Bertos N, Pepin F. Stromal gene expression predicts clinical outcome in breast cancer. Nature Med 2008, 14:518-27.
34. Singer CF, Gschwantler-Kaulich D, Fink-Retter A. Differential gene expression profile in breast cancer-derived stromal fibroblasts. Breast Cancer Res Treat 2008, 110:273-81.
35. Sheehan KM, Gulmann C, Eichler GS. Signal pathway profiling of epithelial and stromal compartments of colonic carcinoma reveals epithelial-mesenchymal transition. Oncogene 2008, 27:323-31.
36. Hasegawa M, Furuya M, Kasuya Y. CD151 dyanmicx in carcinoma-stroma interaction: integrin expression, adhesion strength and proteolytic activity. Lab Invest 2007, 87:882-92.
37. Loussouarn D, Campion L, Sagan C. Prognostic impact of syndecan-1 expression in invasive ductal carcinomas. Br J Cancer 2008, 98:1993-8.
38. Studebaker AW, Storci G, Werbeck JL. Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner. Cancer Res 2008, 68:9087-95.
39. Baak JP, Colpaert CG, van Diest PJ. Multivariate prognostic evaluation of the mitotic activity index and fibrotic focus in node-negative invasive breast cancers. Eur J Cancer 2005, 41:2093-101.
40. Colpaert C, Vermeulen PB, van Beest P. Intratumoral hypoxia resulting in the presence of a fibrotic focus is an independent predictor of early distant relapse in lymph node-negative breast cancer patients. Histopathology 2001, 39:416-25.